April 27, 2007
In a recent peptide quality validation study conducted by Covance Research Products, New England Peptide, LLC (NEP) outperformed eight other peptide providers.
The Peptide Comparison Study evaluated the performance of nine peptide providers across key product and service quality criteria. Each company synthesized the same peptide sequence for the production of custom polyclonal antibodies. The resulting antibody was analyzed for mean antibody titer, determined by the Enzyme-Linked Immuno Sorbent Assay (ELISA) on the associated serum.
The peptide NEP produced for the study generated an antibody with an ELISA titer twice that of the closest competitor for all bleeds analyzed. The study also ranked NEP first in customer service among the nine companies.
"The study provides concrete data that distinguishes NEP in the industry," says Dave Robinson, NEP's CEO. "Since drug discovery project success is unquestionably linked to the quality of the active ingredient, NEP welcomed this opportunity to compare quality and service with others in the market. The results speak for themselves."